文献速递痛风与晶体性关节病

基于人工智能的痛风管理系统降低慢性肾脏病发生率并提高血尿酸达标率

An artificial intelligence-based gout management system reduced chronic kidney disease incident and improved target serum urate achievement.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

一项观察性研究将基于人工智能的痛风智能管理系统(GIMS)与标准电子病历系统(EMRS)的痛风队列按倾向评分1:2匹配,评估4年随访期间慢性肾脏病(CKD)发生率和降尿酸治疗(ULT)达标情况。GIMS组CKD≥3期发生率低于EMRS组,且更多患者达到血尿酸<6.0 mg/dl。

要点

  • GIMS组CKD≥3期发生率为4.1/100人年,EMRS组为7.7/100人年。
  • GIMS组49.8%患者达到血尿酸<6.0 mg/dl,EMRS组为25.9%(P<0.001)。
  • GIMS与CKD≥3期发生率降低及血尿酸达标率提高相关。

核心结论

  • 应用基于人工智能的痛风智能管理系统与痛风患者慢性肾脏病≥3期发生率降低及血尿酸达标率提高相关。
  • 痛风智能管理系统是改善真实世界肾脏结局和降尿酸治疗成功的一种新方法。

研究设计与样本

  • 观察性研究,比较倾向评分匹配的痛风队列,来自基于人工智能的痛风智能管理系统(GIMS)和标准电子病历系统(EMRS)临床数据库。
  • 采用1:2倾向评分匹配队列设计,随访4年,评估AI系统对CKD结局和ULT效果的影响。
  • 所有患者均有痛风且起始估算肾小球滤过率>60 ml/min。

主要发现

  • 与EMRS相比,GIMS与CKD≥3期发生率降低相关:GIMS组新发CKD≥3期169/4117例(发生率4.1/100人年),EMRS组164/2128例(发生率7.7/100人年)。
  • 随访期间GIMS组达到血尿酸<6.0 mg/dl的比例高于EMRS组(49.8% vs 25.9%,P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Stage ≥3 chronic kidney disease (CKD) affects ∼25% of people with gout. The effects of urate-lowering therapy (ULT) on CKD incidence and progression have remained inconclusive. Here, we assessed the impact of a gout ULT clinic intervention using artificial intelligence (AI) on CKD incidence and achievement of serum urate (SU) target. METHODS: An observational study compared propensity score (PS)-matched gout cohorts from an AI-based Gout Intelligent Management System (GIMS) and a standard Electronic Medical Records system (EMRS) clinic database. The GIMS included a mobile application, data fusion interface and modules for expert consultation and laboratory results management. All patients had gout and a starting estimated glomerular filtration rate >60 ml/min. Using a 1:2 PS-matched cohort study design, we assessed the impact of the AI-based system on CKD outcomes and ULT effectiveness over 4 years of follow-up. RESULTS: Compared with EMRS, GIMS was associated with reduced incidence of CKD stage ≥3. Specifically, 169/4117 new-onset CKD stage ≥3 (incidence 4.1 per 100 person-years) with GIMS compared with 164/2128 with EMRS (incidence 7.7 per 100 person-years) during follow-up. More participants achieved SU <6.0 mg/dl with GIMS versus EMRS during follow-up (49.8% vs 25.9%, P < 0.001). CONCLUSION: Application of the artificial intelligence-based Gout Intelligent Management System was associated with lower incidence of chronic kidney disease stage ≥3 and superior target serum urate achievement in people with gout. The Gout Intelligent Management System represents a novel approach to improve real-world renal outcomes and urate-lowering therapy success in gout.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Qi H, Lu J, Dalbeth N, et al. An artificial intelligence-based gout management system reduced chronic kidney disease incident and improved target serum urate achievement. Rheumatology (Oxford). 2025. PMID: 39504469. doi:10.1093/rheumatology/keae616

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。